Latest filings (excl ownership)
6-K
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer
15 Apr 24
20-F
2023 FY
Annual report (foreign)
20 Mar 24
6-K
Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints
19 Mar 24
6-K
Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results
5 Mar 24
6-K
Nyxoah Announces 2024 Strategic Priorities
17 Jan 24
6-K
Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023
9 Jan 24
6-K
Current report (foreign)
11 Dec 23
6-K
Nyxoah Reports Third Quarter 2023 Financial and Operating Results
8 Nov 23
6-K
Nyxoah Announces Partnership with ResMed in Germany
29 Sep 23
6-K
Nyxoah Reports Second Quarter and First Half 2023 Financial and Operating Results
8 Aug 23
6-K
Information on the total number of voting rights and shares
28 Jul 23
6-K
Nyxoah Reports First Quarter 2023 Financial and Operating Results
16 May 23
6-K
Current report (foreign)
15 May 23
6-K
Nyxoah Appoints Christoph Eigenmann as Chief Commercial Officer
11 May 23
6-K
Current report (foreign)
20 Apr 23
6-K
Current report (foreign)
13 Apr 23
6-K
Nyxoah Raises $3 Million from an At-the-Market Equity Offering
27 Mar 23
6-K
Nyxoah Announces a $15 Million Private Placement Financing
23 Mar 23
20-F
2022 FY
Annual report (foreign)
22 Mar 23
6-K
Nyxoah Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
22 Mar 23
6-K
Current report (foreign)
15 Mar 23
6-K
Nyxoah Announces Achievement of Key Clinical and Regulatory Milestones
6 Mar 23
S-8
Registration of securities for employees
25 Jan 23
6-K
Nyxoah Appoints Mr. Daniel Wildman to its Board of Directors
9 Jan 23
EFFECT
Notice of effectiveness
9 Jan 23
CORRESP
Correspondence with SEC
4 Jan 23
6-K
Information on the total number of voting rights and shares
3 Jan 23
UPLOAD
Letter from SEC
29 Dec 22
6-K
Nyxoah Files Shelf Registration Statement and Announces At-the-Market Equity Offering Program
22 Dec 22
F-3
Shelf registration (foreign)
22 Dec 22
6-K
Nyxoah Reports Third Quarter 2022 Financial and Operating Results
8 Nov 22
6-K
Nyxoah announces Change to Board of Directors
24 Oct 22
6-K
Current report (foreign)
19 Oct 22
6-K
Information on the total number of voting rights and shares
3 Oct 22
6-K
Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results
8 Aug 22
6-K
Nyxoah and Acurable Enter into Distribution Agreement in Germany for the AcuPebble SA100 Home Sleep Test
2 Aug 22
6-K
Current report (foreign)
20 Jul 22
6-K
Nyxoah Announces CE Mark Approval for Genio® 2.1
19 Jul 22
6-K
Nyxoah Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio® in Complete Concentric Collapse Patients
11 Jul 22
6-K
Information on the total number of voting rights and shares
1 Jul 22
Latest ownership filings
SC 13G/A
TOGETHER PARTNERSHIP
14 Feb 24
SC 13G/A
Taub Robert
14 Feb 24
SC 13G/A
RESMED INC
6 Jul 23
SC 13G
RESMED INC
6 Apr 23
SC 13D/A
Cochlear Ltd
29 Mar 23
SC 13G
TOGETHER PARTNERSHIP
14 Feb 22
SC 13G
Taub Robert
11 Feb 22
SC 13G
Gilde Healthcare Holding B.V.
10 Feb 22
SC 13D
Cochlear Ltd
16 Jul 21